ForSight Robotics completes $125M Series B funding to address global surgeon shortage

(Image Credit: AdobeStock/Alex)

ForSight Robotics has completed a $125 million Series B round of funding, led by Eclipse. The company plans to use this investment to accelerate the next growth phase for the ORYOM Platform, a robotic surgery platform for cataracts and other eye diseases. The company is preparing to launch first-in-human clinical trials this year.

In addition to Eclipse, the company’s press release¹ notes that the funding round included significant participation from an undisclosed strategic investor, as well as the Adani Group, Reiya Ventures, Frederic Moll, MD, and other existing investors. These investments bring ForSight Robotics’ total funding to $195 million.

Joseph Nathan, MD, ForSight Robotics’ cofounder, president, and chief medical officer, says, “We see ophthalmology as the next frontier in the robotics revolution—much like general surgery was before the rise of Intuitive Surgical. With a comparable market size and an urgent global need, our opportunity ahead is immense. Through our latest funding round, we will bring the same level of transformative impact to eye surgery, with technology designed specifically for its unique precision and complexity.”¹

The company notes that their ORYOM Platform is engineered for highly precise and consistent ophthalmic procedures and will begin with cataract surgeries. Utilizing artificial intelligence–based algorithms, advanced computer vision, and micromechanics, the platform is expected to deliver dexterity and maneuverability while providing surgeons with an improved ergonomic experience. The ORYOM Platform can reach any point within the human eye, allowing surgeons to navigate complex angles and ensuring access to both anterior and posterior segments, setting the stage for glaucoma and retinal surgical treatment.¹

The Series B funding follows a period of rapid growth and key company achievements. Over the past year, ForSight Robotics has expanded its executive team, achieved ISO 13485:2016 certification, a critical regulatory milestone demonstrating the company’s commitment to safety and quality, and doubled in size, surpassing 110 employees as it grows to meet increasing demand. To date, over 2 dozen ophthalmic surgeons have successfully completed hundreds of procedures on animal eye models with the ORYOM Platform. ForSight Robotics is set to begin robotic cataract surgery clinical trials in the coming year.¹

Reference

1. ForSight Robotics secures $125M in Series B funding, addressing global surgeon shortage and exploding demand for ophthalmic surgery. ForSight Robotics. June 24, 2025. Accessed June 24, 2025. https://www.businesswire.com/news/home/20250624465565/en/ForSight-Robotics-Secures-%24125M-in-Series-B-Funding-Addressing-Global-Surgeon-Shortage-and-Exploding-Demand-for-Ophthalmic-Surgery